Volume : 10, Issue : 05, May – 2023
Title:
16.EXPLORING THE BENEFITS OF CLINICAL PHARMACIST’S COUNSELING IN ENHANCING THE MEDICATION COMPLIANCE AND LOW-DENSITY LIPOPROTEIN MANAGEMENT OF HYPERCHOLESTEROLEMIC PATIENTS
Authors :
Dr. Pavan Kumar Yanamadala*, Lalitha Sanjana Nallaparaju, Lakshmi Srilekha Danturthi, Borusu Balavendra Srinivas
Abstract :
Low-Density Lipoprotein Cholesterol reduction reduces the risk of recurrent Myocardial Infarction and death in Coronary Artery Disease patients and in unhealthy individuals. Reduced levels of low-density lipoprotein also inhibit the development of coronary atherosclerosis. By preparing and encouraging patients to adhere to their pharmacotherapeutic regimens, dietary modifications, and management plans, clinical pharmacists can help to ensure that pharmacotherapy has beneficial results. It is clear that the initiatives to increase adherence and ongoing lipid-lowering medication use in high-risk patients are required. Long-term face-to-face counseling is necessary for effective care but may not be practical for many patients. A different strategy is to follow up by telephone. So, in high-risk hypercholesterolemic patients, we evaluated the effect of personalized telephone follow-up on the rate of compliance. As shown in this study, compared to patients without clinical pharmacist management of Dyslipidemia, patients with multiple risk factors who are treated by an interdisciplinary medical team that includes clinical pharmacists in lipid management experienced greater reductions in Low-Density Lipoprotein levels. Improved intermediate results in achieving lipid goals were obtained from the Clinical Pharmacist’s active participation in lipid management for all patients with elevated Low-Density Lipoprotein Levels. Medication Adherence was also assessed using the Morisky Medication Adherence Scale and the mean scores for the Intervention group showed an increased rate of medication adherence when compared to the control group without intervention. The mean score of 5.15 got increased to 6.85 in the Intervention group after 3 months whereas the mean score of 5.125 got a slight increase to 5.225 in the control group. These interim results could eventually lead to fewer long-term cardiovascular events and better patient quality of life.
Keywords: Low-Density Lipoprotein Management, Clinical Pharmacist Interventions, Medication Adherence, Treatment Compliance, Coronary Artery Disease, Hypercholesterolemia
Cite This Article:
Please cite this article in press Pavan Kumar Yanamadala et al, Exploring The Benefits Of Clinical Pharmacist’s Counselling In Enhancing The Medication Compliance And Low-Density Lipoprotein Management Of Hypercholesterolemic Patients., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
References:
1. The Lipid Research Clinics Coronary Primary Prevention Trial results I. Reduction in Incidence of coronary heart disease. Journal of American Medical Association. 1984;251: 351-364
2. The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relationship of reduction in Incidence of coronary heart disease to Cholesterol Lowering. Journal of American Medical Association. 1984; 251:365-374
3. Frick M, Elo O, Haapa K, Heinonen O, Heinsalmi P, Helo P, Helsinki Heart Study: Primary Prevention Trial with Gemfibrozil in Middle-aged Men with Dyslipidemia. Safety of Treatment, changes in risk factors and incidence of Coronary Heart disease. Journal of American Medical Association. 1987; 317:1237-45
4. Pedersen T, Kjekshus J, Berg K. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9.
5. Sacks F, Pfeffer M, Noye L and the CaRECT Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine. 1996;335:1001-9.
6. Shepherd J, Cobbe S, Ford 1, and the West of Scotland Coronary Prevention Study (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.New England Journal of Medicine. 1995;333:1301-7.
7. Downs J, Clearfield M, Weiss S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TesCAPS. Journal of American Medical Association.1998;279:1615-22.
8. Superko R. Prevention and regression of atherosclerosis with drug therapy. Clinical Cardiology. 1991;14:40-7.
9. Superko H, Krauss R. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation.1994:90:1056-693.
10. Andrade SE, Walker AM, Gottlieb LK, HollenbergNK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings?New England Journal of Medicine.1995;332:1125-1131.
11. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. The Annals of Pharmacotherapy.2008; 42(9):1195-1207.
12. Padiyara RS, DSouza JJ, Rihani RS.Clinical pharmacist intervention and the proportion of diabetes patients attaining prevention objectives in a multispecialty medical group. Journal of Managed Care Speciality Pharmacy.2011; 17(6): 456-462.
13. Keefe JH, Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer.Mayo Clinical Proceedings.2004, 79: 101-108.
14. Cordain L, Eaton SB, Miller JB, et al. The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic.European Journal of Clinical Nutrition.2002; 56(1): S42-S52.
15. O’Keefe JI, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. Journal of American College Cardiology.2004; 43: 2142-2146.
16. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis.American Journal of Clinical Nutrition.1999; 69:30-42.
17. Demonty I, Ras RT, van der Knaap HC, et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intakeJournal of Nutrition.2009;139: 271-284.
18. Sabate J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Archives of Internal Medicine.2010;170: 821-827.
19. Taku K, Umegaki K, Sato Y, et al. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition.2007, 85: 1148-1156.
20. Williams PT, Krauss RM, Kindel-RK2227)S, et al. Relationship of dietary fat, protein, cholesterol, and fiber intake to atherogenic lipoproteins in men. American Journal of Clinical Nutrition.1986; 44: 788-797.
21. Siri PW, Krauss RM. Influence of dietary carbohydrate and fat on LDL and HDL particle distributions. Current Atherosclerosis Reports.2005; 7:455-459.
22. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence.European Journal of Clinical Nutrition.2009; 63(2): $5-S21.
23. Richard C, Couture P, Desroches S, et al. Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome. British Journal of Nutrition.2012; 107:705—711.
24. Georgousopoulou EN, Pitsavos C, Panagiotakos D, et al. Adherence to Mediterranean is the most important protector against the development of fatal and non-fatal cardiovascular event: 10-year follow-up (2002- 2012) of the Attica study. Journal of the American College of Cardiology.2015; 65: 1449.
25. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet.1990; 336: 129-133.
26. Belardinelli R, Paolini 1, Cianci G, et al. Exercise training intervention after coronary angioplasty: the ETICA trial. Journal of the American College of Cardiology.2001; 37: 1891-1900.
27. Wosornu D, Bedford D, Ballantyne D. A comparison of the effects of strength and aerobic exercise training on exercise capacity and lipids after coronary artery bypass surgery. European Heart Journal.1996; 17: 854-863.
28. Yu CM, Li LS, Ho HH, et al. Long-term changes in exercise capacity, quality of life, body anthropometry, and lipid profiles after a cardiac rehabilitation program in obese patients with coronary heart disease. American Journal of Cardiology.2003; 91:321-325
29. Wood PD, Stefanick ML, Dreon DM, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise.New England Journal of Medicine.1988; 319: 1173-1179.
30. Halle M, Berg A, Konig D, et al. Differences in the concentration and composition of low-density lipoprotein subfraction particles between sedentary and trained hypercholesterolemic men. Metaholism.1997; 46:186—-I91.
31. Williams PT, Krauss RM, Vranizan KM, et al. Effects of exercise-induced weight loss on low density lipoprotein subfractions in healthy men. Arteriosclerosis.1989;9: 623-632.
32. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins.New England Journal of Medicine.2002; 347: 1483-1492.
33. Ahmed HM, Blaha MJ, Nasir K, et al. Effects of physical activity on cardiovascular disease.American Journal of Cardiology.2012; 109: 288-295.
34. Scirica BM, Cannon CP. Treatment of elevated cholesterol.Circulation.2005;111:360-363.